DNA Biomed Stock Target Price and Analyst Consensus
| DNA Stock | ILS 89.00 5.00 5.95% |
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize DNA Biomed price targets
DNA Biomed's stock target price is an estimate of its future price, usually made by analysts. Using DNA Biomed's target price to determine if it is a suitable investment can be done through the following steps:- Look at DNA Biomed's target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if DNA Biomed's stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional DNA Biomed Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of DNA Biomed is a key component of DNA Biomed valuation and have some predictive power on the future returns of a DNA Biomed.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of DNA Biomed's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Driverless Cars Invested few shares | |
 | Momentum Invested few shares | |
 | Adviser Favorites Invested few shares | |
 | Macroaxis Index Invested few shares | |
 | Automobiles and Trucks Invested over 200 shares | |
 | Baby Boomer Prospects Invested over 70 shares | |
 | Banking Invested over 30 shares | |
Check out Macroaxis Advice on DNA Biomed to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. Note that the DNA Biomed Solns information on this page should be used as a complementary analysis to other DNA Biomed's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for DNA Stock analysis
When running DNA Biomed's price analysis, check to measure DNA Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DNA Biomed is operating at the current time. Most of DNA Biomed's value examination focuses on studying past and present price action to predict the probability of DNA Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DNA Biomed's price. Additionally, you may evaluate how the addition of DNA Biomed to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
The data published in DNA Biomed's official financial statements usually reflect DNA Biomed's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of DNA Biomed Solns. For example, before you start analyzing numbers published by DNA accountants, it's critical to develop an understanding of what DNA Biomed's liquidity, profitability, and earnings quality are in the context of the Electronic Equipment, Instruments & Components space in which it operates.
Please note, the presentation of DNA Biomed's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, DNA Biomed's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in DNA Biomed's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of DNA Biomed Solns. Please utilize our Beneish M Score to check the likelihood of DNA Biomed's management manipulating its earnings.